Clinical Cancer Research

Table of Contents

American Association for Cancer Research

December 1, 2019 • Volume 25 • Number 23

SPECIAL FEATURES

Highlights of This Issue 6885

CCR Translations

6887 **Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats**
Linghua Wang and Jaffer A. Ajani
See related articles, p. 7024 and p. 7035

6890 **Today's Special on the Anticancer Menu: Immunomodulation by Antifolates**
Aitziber Buque, Lorenzo Galluzzi, and Noelia Casares
See related article, p. 7175

6893 **ctDNA in Gastric and Gastroesophageal Cancer: Prognostic, Predictive, or Preliminary?**
Alexander M. Frankell and Elizabeth C. Smyth
See related article, p. 7098

6896 **Class(y) Dissection of *BRAF* Heterogeneity: Beyond Non-V600**
Elisa Fontana and Nicola Valeri
See related article, p. 7089

Reviews

6899 **Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies**
Christine M. Parseghian, Stefania Napolitano, Jonathan M. Loree, and Scott Kopetz

6909 **Use of Circulating Tumor DNA for Cancer Immunotherapy**
Alexandra Snyder, Michael P. Morrissey, and Matthew D. Hellmann

Perspectives

6916 **The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance**
Himisha Beltran, Andrew Hruszkewycz, Howard I. Scher, Jeffrey Hildesheim, Jennifer Isaacs, Evan Y. Yu, Kathleen Kelly, Daniel Lin, Adam Dicker, Julia Arnold, Toby Hecht, Max Wicha, Rosalie Sears, David Rowley, Richard White, James L. Gulley, John Lee, Maria Diaz Meco, Eric J. Small, Michael Shen, Karen Knudsen, David W. Goodrich, Tamara Lotan, Amina Zoubeidi, Charles L. Sawyers, Charles M. Rudin, Massimo Loda, Timothy Thompson, Mark A. Rubin, Abdul Tawab-Amiri, William Dahut, and Peter S. Nelson

6925 **Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)**
Holly A. Massett, Grace Mishkin, Jeffrey A. Moscow, Amy Gravell, Michael Steketee, Martha Kruhm, Sae H. Han, Barbara Barry, Michael Montello, James Zwiebel, Jeffrey S. Abrams, James H. Doroshow, and S. Percy Ivy

CLINICAL TRIAL BRIEF REPORT

6932 **Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma**
Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, Ted A. Gooley, Darrell R. Fisher, Leona A. Holmberg, Robert S. Miyaoka, Brenda M. Sandmaier, Damian J. Green, and Ajay K. Gopal

CLINICAL TRIALS: TARGETED THERAPY

6939 **Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist ^{177}Lu-Satoreotide Tetraxetan**
Diane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A. O'Donoghue, Simone Krebs, Kevin D. Staton, Serge K. Lyashchenko, Jason S. Lewis, Nitya Raj, Mithat Gönen, Christian Lohrmann, Lisa Bodei, and Wolfgang A. Weber

6948 **Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma**
Reena P. Thomas, Seema Nagpal, Michael Iv, Scott G. Soltys, Sophie Bertrand, Judith S. Pelpola, Robyn Ball, Jaden Yang, Vandana Sundaram, Jonathan Lavezo, Donald Born, Hannes Vogel, J. Martin Brown, and Lawrence D. Recht

6958 **Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study**
Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, and David P. Carbone

Table of Contents

6967 **Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial**
Li Li, Liyan Jiang, Yubo Wang, Yizhuo Zhao, Xiao-Ju Zhang, Guoming Wu, Xiangdong Zhou, Jianguo Sun, Jun Bai, Biyong Ren, Kun Tian, Zhi Xu, Hua-liang Xiao, Qi Zhou, Rui Han, Hengyi Chen, Haidong Wang, Zhenzhou Yang, Chan Gao, Shangli Cai, and Yong He

6976 **Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes**
Valeria Santini, David Valcárcel, Uwe Platzbecker, Rami S. Komrokji, Ann L. Cleverly, Michael M. Lahn, Jan Janssen, Yumin Zhao, Alan Chiang, Aristoteles Giagounidis, Susan C. Guba, Ivelina Gueorguieva, Allicia C. Girvan, Mariana da Silva Ferreira, Tushar D. Bhagat, Kith Pradhan, Ulrich Steidl, Ashwin Sridharan, Britta Will, and Amit Verma

6986 **A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma**
Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid, Jay M. Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, and Owen A. O'Connor

CLINICAL TRIALS: IMMUNOTHERAPY

6995 **Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma**
Zi-Xun Yan, Li Li, Wen Wang, Bin-Shen OuYang, Shu Cheng, Li Wang, Wen Wu, Peng-Peng Xu, Muharrem Muftuoglu, Ming Hao, Su Yang, Mu-Chen Zhang, Zhong Zheng, James Li, and Wei-Li Zhao

7004 **A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma**
Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao-Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, and Edward M. Newman

7014 **Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer**
Christian Lohrmann, Eileen M. O'Reilly, Joseph A. O'Donoghue, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Serge K. Lyashchenko, Shutian Ruan, Rebecca Teng, Wolfgang Scholz, Paul W. Maffuid, Jason S. Lewis, and Wolfgang A. Weber

PRECISION MEDICINE AND IMAGING

7024 **Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade**
Andrew Georgiadis, Jennifer N. Durham, Laurel A. Keefer, Bjarne R. Bartlett, Magdalena Zielonka, Derek Murphy, James R. White, Steve Lu, Ellen L. Verner, Finey Ruan, David Riley, Robert A. Anders, Erika Gedvilaite, Sam Angiuoli, Siân Jones, Victor E. Velculescu, Dung T. Le, Luis A. Diaz Jr, and Mark Sausen
See related commentary, p. 6887

7035 **Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel**
Jason Willis, Martina I. Lefterova, Alexander Artyomenko, Pashtoon Murtaza Kasi, Yoshiaki Nakamura, Kabir Mody, Daniel V.T. Catenacci, Marwan Fakih, Catalin Barbacioru, Jing Zhao, Marcin Sikora, Stephen R. Fairclough, Hyuk Lee, Kyoung-Mee Kim, Seung Tae Kim, Jinchul Kim, Danielle Gavino, Manuel Benavides, Nir Peled, Timmy Nguyen, Mike Cusnir, Ramez N. Eskander, Georges Azzi, Takayuki Yoshino, Kimberly C. Banks, Victoria M. Raymond, Richard B. Lanman, Darya I. Chudova, AmirAli Talasaz, Scott Kopetz, Jeeyun Lee, and Justin I. Odegaard
See related commentary, p. 6887

7046 **Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19**
Maria Ormhøj, Irene Scarfò, Maria L. Cabral, Stefanie R. Bailey, Selena J. Lorrey, Amanda A. Bouffard, Ana P. Castano, Rebecca C. Larson, Lauren S. Riley, Andrea Schmidts, Bryan D. Choi, Rikke S. Andersen, Oriane Cédile, Charlotte G. Nyvold, Jacob H. Christensen, Morten F. Gjerstorff, Henrik J. Ditzel, David M. Weinstock, Torben Barington, Matthew J. Frigault, and Marcela V. Maus

7058 **Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)**
Kezhong Chen, Heng Zhao, Yanbin Shi, Fan Yang, Lien Tu Wang, Guannan Kang, Yuntao Nie, and Jun Wang

Table of Contents

7068 **Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array**
Jiuyi Li, Yang Xue, Anna Wenger, Yingyu Sun, Zheng Wang, Chuanbao Zhang, Yunqiu Zhang, Boglarka Fekete, Bertil Rydenhag, Asgeir Store Jakola, Tao Jiang, Helena Carén, and Xiaolong Fan

7078 **Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer**
Loren K. Mell, Hanjie Shen, Phuc Felix Nguyen-Tân, David I. Rosenthal, Kaveh Zakeri, Lucas K. Vitzthum, Steven J. Frank, Peter B. Schiff, Andy M. Trotti III, James A. Bonner, Christopher U. Jones, Sue S. Yom, Wade L. Thorstad, Stuart J. Wong, George Shenouda, John A. Ridge, Qiang E. Zhang, and Quynh-Thu Le

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

7089 **Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer**
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna R. Parikh, Hideaki Bando, Emily E. Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire N. Thant, Elisa de Stanchina, Neal Rosen, Ryan B. Corcoran, Takayuki Yoshino, Zhan Yao, and Hiromichi Ebi
See related commentary, p. 6896

7098 **Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma**
Steven B. Maron, Leah M. Chase, Samantha Lomnicki, Sara Kochanny, Kelly L. Moore, Smita S. Joshi, Stacie Landron, Julie Johnson, Lesli A. Kiedrowski, Rebecca J. Nagy, Richard B. Lanman, Seung Tae Kim, Jeeyun Lee, and Daniel V.T. Catenacci
See related commentary, p. 6893

7113 **Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach**
Jason C. Chang, Deepu Alex, Matthew Bott, Kay See Tan, Venkatraman Seshan, Andrew Golden, Jennifer L. Sauter, Darren J. Buonocore, Chad M. Vanderbilt, Sounak Gupta, Patrice Desmeules, Francis M. Bodd, Gregory J. Riely, Valerie W. Rusch, David R. Jones, Maria E. Arcila, William D. Travis, Marc Ladanyi, and Natasha Rekhtman

7126 **NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced *In Vivo* Persistence and Antitumor Activity against Neuroblastoma**
Xin Xu, Wei Huang, Andras Heczey, Daofeng Liu, Linjie Guo, Michael Wood, Jingling Jin, Amy N. Courtney, Bin Liu, Erica J. Di Pierro, John Hicks, Gabriel A. Barragan, Ho Ngai, Yuhui Chen, Barbara Savoldo, Gianpietro Dotti, and Leonid S. Metelitsa

7139 **BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer**
Louise Walsh, Kathryn E. Haley, Bruce Moran, Brian Mooney, Finbarr Tarrant, Stephen F. Madden, Alessandra Di Grande, Yue Fan, Sudipto Das, Oscar M. Rueda, Catríona M. Dowling, Damir Varešlija, Suet-Feung Chin, Sabine Linn, Leonie S. Young, Karin Jirström, John P. Crown, Rene Bernards, Carlos Caldas, William M. Gallagher, Darran P. O'Connor, and Tríona Ní Chonghaile

7151 **A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization**
Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai, Kenji Hirotani, Yusuke Ogitani, Akiko Zembutsu, Manabu Abe, Yuki Kaneda, Naoyuki Maeda, Yoshinobu Shiose, Takuma Iguchi, Tomomichi Ishizaka, Tsuyoshi Karibe, Ichiro Hayakawa, Koji Morita, Takashi Nakada, Taisei Nomura, Kenichi Wakita, Takashi Kagari, Yuki Abe, Masato Murakami, Suguru Ueno, and Toshinori Agatsuma

7162 **Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death**
Fieke E.M. Froeling, Manojit Mosur Swamynathan, Astrid Deschênes, Iok In Christine Chio, Erin Brosnan, Melissa A. Yao, Priya Alagesan, Matthew Lucito, Juying Li, An-Yun Chang, Lloyd C. Trotman, Pascal Belleau, Youngkyu Park, Harry A. Rogoff, James D. Watson, and David A. Tuveson

7175 **The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy**
David A. Schaer, Sandaruwan Geeganage, Nelusha Amaladas, Zhao Hai Lu, Erik R. Rasmussen, Andreas Sonyi, Darin Chin, Andrew Capen, Yanxia Li, Catalina M. Meyer, Bonita D. Jones, Xiaodong Huang, Shuang Luo, Carmine Carpenito, Kenneth D. Roth, Alexander Nikolayev, Bo Tan, Manisha Brahmachary, Krishna Chodavarapu, Frank C. Dorsey, Jason R. Manro, Thompson N. Doman, Gregory P. Donoho, David Surguladze, Gerald E. Hall, Michael Kalos, and Ruslan D. Novosiadly
See related commentary, p. 6890

7189 **Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas**
Alexandros Papachristodoulou, Manuela Silginer, Michael Weller, Hannah Schneider, Kathy Hasenbach, Michel Janicot, and Patrick Roth

7202 **Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation**
Victoria E. Wang, Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson, Anatoly Urisman, David P. Carbone, Keith T. Flaherty, Rene Bernards, Piro Lito, Jeff Settleman, and Frank McCormick

Table of Contents

7218 **NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells**
Cynthia Chauvin, Noémie Joalland, Jeanne Perroteau, Ulrich Jarry, Laura Lafrance, Catherine Willem, Christelle Retière, Lisa Oliver, Catherine Gratas, Laetitia Gautreau-Rolland, Xavier Saulquin, François M. Vallette, Henri Vié, Emmanuel Scotet, and Claire Pecqueur

7229 **Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression**
Yirui Gui, Adriana Aguilar-Mahecha, Urszula Krzemien, Abdel Hosein, Marguerite Buchanan, Josiane Lafleur, Michael Pollak, Cristiano Ferrario, and Mark Basik

7243 **Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment**
Ren Luo, Elke Firat, Simone Gaedicke, Elena Guffart, Tsubasa Watanabe, and Gabriele Niedermann

7256 **Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy**
Reinout H. de Roest, Steven W. Mes, Jos B. Poell, Arjen Brink, Mark A. van de Wiel, Elisabeth Bloemena, Elena Thai, Tito Poli, C. René Leemans, and Ruud H. Brakenhoff

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The image shows a lung adenocarcinoma with solid growth pattern. By comprehensive next-generation sequencing (NGS), this tumor had an identical genomic profile to a previously resected adenocarcinoma with entirely different, better-differentiated histologic features. This illustrates histologic progression of lung adenocarcinoma during metastasis, and the utility of NGS in clinical practice for confirming clonally related tumors despite histologic differences. For details, see the article by Chang and colleagues on page 7113 of this issue.